PRESS RELEASE: NACON: FY 2021/22: ANNUAL SALES: 155.9 M€
Press release
Lesquin, 25 April 2022 – 18:00hrs
FY 2021/22, A TRANSITION YEAR
ANNUAL SALES:155.9 M€ (-12.3%)
VERY STRONG GROWTH EXPECTED IN FY2022/23
NACON (ISIN FR0013482791) announced today its sales for the full 2021/22 financial year (period from 1st April until 31st March).
| IFRS – M€ | 2021/22 | 2020/21 | Change |
| Sales | |||
| 1st Quarter | 33.7 | 38.0 | -11.3% |
| 2nd Quarter | 39.3 | 48.6 | -19.1% |
| 3rd Quarter (1) | 51.2 | 48.6 | +5.2% |
| 4th Quarter (Jan. - March) (1) | 31.7 | 42.6 | -25.6% |
| Games | 12.9 | 22.4 | -42.6% |
| Accessories | 17.9 | 19.0 | -6.0% |
| Others(2) | 0.9 | 1.1 | -19.6% |
| Cumulative 12mths(April-March) (1) | 155.9 | 177.8 | -12.3% |
| Games | 54.4 | 69.0 | -21.2% |
| Accessories | 96.6 | 103.1 | -6.3% |
| Others(2) | 4.9 | 5.7 | -13.7% |
| (1) Non audited data | |||
| (2)Mobileand Audio sales |
A fourth quarter impacted by the postponement of the release of several video games
As announced, sales for the 4th quarter of FY 2021/22, at €31.7 M€, were down 25.6% on a like-for-like basis due to the weakness of the publishing business.
GAMES
The Video Games business posted Q4 sales of 12.9 M€, down 42.6%. This change resulted from the postponement of several game releases to FY 2022/2023, in particular the highly awaited Vampire: The Masquerade® - Swansong title to 19 May 2022.
The only release of the quarter, Rugby 22, was well received and outperformed Rugby 20.
The back catalogue* business performed well with sales up 12.7% to 6.9 M€.
ACCESSORIES
The Accessories business held up well against a backdrop of a shortage of consoles and an unfavourable geopolitical and economic environment. Sales were 17.9 M€ for the quarter, down 6.0%.
12-month sales in line with announced targets
For the full FY 2021/2022, sales amounted to 155.9 M€, within the range announced by the Group at the time of the publication of Q3 sales.
Sales were 54.4 M€ (-21.2%) for the Games business and 96.6 M€ (-6.3%) for the Accessories business.
Due to slightly lower than expected sales in Q4, current operating income is expected to be between 17 M€ and 19 M€ for the full year.
Strong acceleration of business and earnings growth expected in 2022/2023
The quantity and quality of the games expected for FY 2022/23 will have a "booster" effect on the activity of this new financial year.
Due to the high level of editorial activity (Vampire: The Masquerade® - Swansong, Zorro The Chronicles, Tour de France 2022 and Pro Cycling Manager), sales in Q1 2022/23 will be up sharply.
In this context, Nacon reiterates its targets of sales ranging between 250 M€ and 300 € for FY 2022/23 with a current operating margin in excess of 20%.
Following the acquisitions of Midgar Studio and Daedalic Entertainment, Nacon will further pursue its external growth strategy in order to strengthen its ability to develop new quality games internally.
Upon release of its FY 2021/22 results on May 30, Nacon will detail its business plan for the current year.
(*) Back catalogue: games released in previous financial years
Next Publication:
Annual Results 2021/22: 30 May 2022 (Press release after close of the Paris stock exchange)
2021-22 ANNUAL SALES 155.9 M€ HEADCOUNT Over 700 employees INTERNATIONAL 20 subsidiaries and a distribution network across 100 countries https://corporate.nacongaming.com/ | NACON is a company of the BIGBEN Group founded in 2019 to optimize its know-how through strong synergies in the video game market. By bringing together its 16 development studios, the publishing of AA video games, the design and distribution of premium gaming devices, NACON focuses 30 years of expertise at the service of players. This new unified business unit strengthens NACON's position in the market, enables it to innovate by creating new unique competitive advantages. Company listed on Euronext Paris, compartment B ISIN : FR0013482791 ; Reuters : NACON.PA ; Bloomberg : NACON:FP PRESS CONTACT Cap Value – Gilles Broquelet gbroquelet@capvalue.fr - +33 1 80 81 50 01 |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bavarian Nordic modtager vaccineordre fra europæisk land efter bekræftede tilfælde af abekopper19.5.2022 11:46:42 CEST | pressemeddelelse
KØBENHAVN, Danmark, 19. maj 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en kontrakt med et unavngivet europæisk land vedrørende levering af koppevaccinen IMVANEX® i forbindelse med nye tilfælde af abekopper, der er identificeret i løbet af maj 2022. Det første europæiske tilfælde blev bekræftet den 7. maj 2022 hos en person, der vendte hjem fra en rejse til Nigeria, hvor abekopper er naturligt forekommende. Efterfølgende er der bekræftet mere end 20 tilfælde i England, Portugal og Spanien, og flere formodede tilfælde er ved at blive undersøgt. De fleste infektioner lader til at være sket lokalt i de tre lande. I USA er der bekræftet et enkelt tilfælde hos en rejsende fra Canada, hvor der endnu ikke foreligger bekræftede tilfælde, men adskillige formodede tilfælde er ved at blive undersøgt. Bavarian Nordics koppevaccine er godkendt i USA under navnet JYNNEOS® og i Canada under navnet IMVAMUNE®. I begge lande er godkendelsen udvidet til at omfatte abek
Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases19.5.2022 11:46:42 CEST | Press release
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022. The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation. Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe a
XPENG Oslo Experience Store Now Open With XPENG G3i and XPENG P5 Available for Local Test Drives19.5.2022 11:00:00 CEST | Press release
XPENG opens its first Brand Experience Store in the Bjørvika area of downtown Oslo on May 19, 2022.The launch of the fully electric XPENG P5 and XPENG G3i makes Norway the first European country to boast the full range of XPENG EVs. Local test drives are now available to customers.XPENG, in June this year, will be participating in the 35th International Electric Vehicle Symposium (EVS35) 2022, the world’s largest international EV event live from Oslo. OSLO, Norway, May 19, 2022 (GLOBE NEWSWIRE) -- XPENG, a leading electric vehicle manufacturer, is taking the next step in its European expansion by opening its first Norwegian Brand Experience Store in the Bjørvika area of Oslo on May 19. This coincides with the official launch of the brand's two latest models, XPENG G3i and XPENG P5. Establishing a Local Presence XPENG is one of the early adopters of a disruptive retail model in the European market, combining direct, in-store sales with wider agency collaboration. In the Oslo Brand Exper
IBFD launches the 2021 Yearbook on Taxpayers’ Rights19.5.2022 10:00:00 CEST | Press release
Today, IBFD launches the 2021 Yearbook on the Protection of Taxpayers’ Rights (OPTR). The book is a compilation of up-to-date information on the effective protection of taxpayers’ rights. AMSTERDAM, May 19, 2022 (GLOBE NEWSWIRE) -- Prof. Dr Pasquale Pistone and Prof. Dr Philip Baker, Directors of IBFD’s OPTR, will present the Yearbook at the 7th International Conference on Taxpayer Rights, hosted by the Center for Taxpayer Rights, explaining some of the main events and trends that arose last year in the protection of taxpayers’ rights around the world. Click here to watch the video. The OPTR reports on the protection of taxpayers’ fundamental rights around the world. The precise and technical information of the OPTR contains reference to taxpayer bills, conventions and statutes, including their judicial and administrative interpretation, which explore how states apply this protection in practice. The OPTR serves as a unique legal basis for developing further research on the legal remed
Centrient Pharmaceuticals announces its achievement of a significant milestone in the clean production of antibiotics19.5.2022 10:00:00 CEST | Press release
Being the first company to publicly announce 100% PNEC compliance for its entire oral antibiotics product range Rijswijk, The Netherlands, May 19, 2022 (GLOBE NEWSWIRE) -- Summary Centrient Pharmaceuticals reached a significant milestone in the clean production of its antibiotics, with the lowest environmental impact and minimizing the potential contribution to antimicrobial resistanceThe company is the first to publicly announce that Its entire supply chain of oral antibiotics – including its own and supplier manufacturing sites - is fully compliant with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry AllianceThis achievement demonstrates Centrient Pharmaceuticals’ commitment and leadership in the responsible production of antibiotics. Centrient Pharmaceuticals announces 100% compliance with the stringent Predicted No Effect Concentration (PNEC) discharge targets set by the AMR Industry Alliance for clean manufacturing of its full oral